Equities analysts expect that Vericel Corporation (NASDAQ:VCEL) will report earnings of ($0.24) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Vericel Corporation’s earnings. Vericel Corporation posted earnings per share of ($0.21) during the same quarter last year, which would indicate a negative year over year growth rate of 14.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, August 14th.
On average, analysts expect that Vericel Corporation will report full-year earnings of ($0.84) per share for the current financial year, with EPS estimates ranging from ($0.93) to ($0.75). For the next financial year, analysts expect that the company will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.65) to ($0.40). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Vericel Corporation.
Vericel Corporation (NASDAQ:VCEL) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.12. The firm had revenue of $9.36 million during the quarter.
Separately, BTIG Research initiated coverage on Vericel Corporation in a research report on Tuesday, June 20th. They issued a “buy” rating and a $6.00 price objective for the company.
Vericel Corporation (NASDAQ:VCEL) traded up 1.49% on Friday, hitting $3.40. The stock had a trading volume of 763,344 shares. The firm’s market cap is $111.40 million. Vericel Corporation has a 1-year low of $2.00 and a 1-year high of $4.55. The firm’s 50-day moving average price is $3.06 and its 200-day moving average price is $2.83.
A hedge fund recently raised its stake in Vericel Corporation stock. Stonepine Capital Management LLC boosted its position in Vericel Corporation (NASDAQ:VCEL) by 73.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,265,323 shares of the biotechnology company’s stock after buying an additional 1,381,523 shares during the period. Vericel Corporation comprises about 5.2% of Stonepine Capital Management LLC’s holdings, making the stock its 8th largest position. Stonepine Capital Management LLC owned about 9.98% of Vericel Corporation worth $9,143,000 at the end of the most recent quarter. 31.94% of the stock is currently owned by institutional investors and hedge funds.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Get a free copy of the Zacks research report on Vericel Corporation (VCEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
